What is the pathophysiology and management of a gout flare?

Pathophysiology of Gout Flares

Gout flares result from the inflammatory response triggered when monosodium urate crystals precipitate in joint spaces and activate the innate immune system, with IL-1β playing a central role in driving the acute inflammatory cascade. 1, 2

Crystal Formation and Deposition

• Chronic hyperuricemia creates the metabolic precondition for monosodium urate crystal formation in joints and periarticular tissues 1, 2
• These crystals deposit locally in joint spaces and bursae, remaining asymptomatic until an inflammatory trigger occurs 1
• The evolutionary loss of uricase in humans is a necessary precondition that allows hyperuricemia to develop, as humans cannot enzymatically break down uric acid like other mammals 2

Inflammatory Cascade

• Monosodium urate crystals provoke acute inflammatory responses by activating the innate immune system 2
• IL-1β is the central mediator of gouty inflammation, driving the characteristic severe pain and joint swelling 2
• This inflammatory synovitis presents as self-limited attacks (flares) that are superimposed on the underlying crystal deposition 1

Paradoxical Flares During Urate-Lowering Therapy

• During the initial phase of urate-lowering therapy, there is an early increase in acute gout attacks despite falling serum urate levels 1
• This paradoxical phenomenon is hypothesized to result from remodeling of articular urate crystal deposits as rapid and substantial lowering of ambient urate concentrations destabilizes existing crystal deposits 1
• The remodeling process causes crystal shedding into the joint space, triggering new inflammatory episodes 1

Renal Contribution

• The kidneys play a central role in urate handling, and impaired renal uric acid excretion is a major contributor to hyperuricemia 2
• Diuretics are the most common iatrogenic cause of gout by reducing renal uric acid excretion 3

Clinical Impact

• Acute gout attacks are debilitating and account for a major component of decreased health-related quality of life in patients with gout 1
• These flares are associated with decreased work productivity and can require emergency medical care or hospitalization in severe cases 1

---

Management of Gout Flares

Acute Flare Treatment

Initiate treatment immediately with corticosteroids, NSAIDs, or colchicine, choosing based on patient comorbidities and contraindications, as early treatment maximizes effectiveness. 1, 4, 5

First-Line Options

• Corticosteroids are recommended as first-line therapy in patients without contraindications due to their safety profile and low cost: oral prednisone 30-35 mg/day for 3-5 days or 0.5 mg/kg/day for 5-10 days 3, 4, 5
• NSAIDs at full anti-inflammatory doses are effective when started promptly, but avoid in patients with renal disease, heart failure, or cirrhosis; use with a proton pump inhibitor if gastrointestinal risk exists 1, 4, 5
• Colchicine is most effective when started within 12 hours of symptom onset: loading dose of 1.2 mg (or 1 mg) followed by 0.6 mg (or 0.5 mg) one hour later 1, 4, 5
• Low-dose colchicine (1.2 mg followed by 0.6 mg 1 hour later) is as effective as higher doses at reducing pain and is associated with fewer gastrointestinal adverse effects 1

Special Considerations

• For single joint involvement, intra-articular corticosteroid injection is recommended 4
• Patients should be educated to self-medicate at the first warning signs to maximize treatment effectiveness 4, 5
• Topical ice and rest of the inflamed joint are useful nonpharmacological adjuncts 6

Dose Adjustments for Renal Impairment

• For acute flare treatment in patients with mild to moderate renal impairment (CrCl 30-80 mL/min), colchicine dose adjustment is not required, but monitor closely for adverse effects 7
• In severe renal impairment (CrCl <30 mL/min), the colchicine treatment course should be repeated no more than once every two weeks 7
• For patients undergoing dialysis, reduce the total colchicine dose for acute flares to a single dose of 0.6 mg, and do not repeat more than once every two weeks 7
• Corticosteroids are generally safer than NSAIDs or colchicine in patients with renal impairment 4

Prophylaxis During Urate-Lowering Therapy Initiation

Prophylactic anti-inflammatory therapy is mandatory for all patients when initiating urate-lowering therapy and should continue for at least 6 months to prevent mobilization flares. 1, 3, 4, 5

Prophylaxis Regimens

• Colchicine 0.5-1 mg daily is first-line prophylaxis (reduce to 0.5 mg daily or every other day if CrCl 30-50 mL/min) 3, 4, 5
• Low-dose NSAIDs are appropriate alternatives to colchicine unless contraindicated 3, 4
• Low-dose corticosteroids can be used when colchicine and NSAIDs are contraindicated 3

Duration of Prophylaxis

• Continue prophylaxis for a minimum of 6 months when starting urate-lowering therapy 1, 3, 4, 5
• Moderate-quality evidence supports continuing prophylaxis for more than 8 weeks, as flare rates approximately doubled when prophylaxis was discontinued after 8 weeks 1
• Analysis of Phase III trials found that prophylaxis for up to 6 months provided greater benefit than 8 weeks, with no increase in adverse events 8
• Continue prophylaxis while attacks persist, even beyond 6 months if necessary 5

Critical Pitfall to Avoid

• Do not stop urate-lowering therapy during acute attacks once started, as this perpetuates the cycle of recurrent flares 3, 5
• Treatment of acute gout flares with colchicine is not recommended in patients already receiving prophylactic colchicine and CYP3A4 inhibitors 7

Long-Term Urate-Lowering Therapy

Indications for Initiating ULT

• Do not initiate long-term urate-lowering therapy after a first gout attack or in patients with infrequent attacks (<2 per year) 1, 4
• Initiate ULT in patients with: recurrent gout flares (≥2 per year), one or more palpable tophi, chronic synovitis due to gout, urate arthropathy, or renal stones 1, 4, 5
• Consider early ULT initiation if the patient presents with young age (<40 years) and very high uric acid levels (>8 mg/dL), or significant comorbidities 5

ULT Initiation and Monitoring

• Start allopurinol at 100 mg daily, increasing by 100 mg every 2-4 weeks until serum uric acid <6 mg/dL (360 μmol/L) 1, 3, 4, 5
• Target serum uric acid <6 mg/dL lifelong to steadily reduce articular and periarticular urate crystal deposits 1, 3, 4, 5
• ULT can be started during an acute attack; there is no need to wait for the attack to resolve 5
• Regularly monitor serum uric acid levels to ensure target achievement 5

Evidence on ULT Effectiveness

• High-quality evidence shows that urate-lowering therapy does not reduce the risk for acute gout attacks in the first 6 months 1
• Observational evidence shows that patients who attained lower urate levels after 1 year of urate-lowering therapy had fewer gout flares 1
• By the end of treatment, patients with mean postbaseline serum urate <6.0 mg/dL had fewer flares than those with levels ≥6.0 mg/dL 8

Allopurinol Dose Adjustment in Renal Impairment

• Allopurinol dosing should be adjusted based on creatinine clearance 4
• In severe renal failure (CrCl <30 mL/min) and end-stage renal disease requiring dialysis, start allopurinol at 0.3 mg/day (note: this appears to be an error in the source; standard allopurinol dosing would be different) 7

Lifestyle Modifications

• Weight loss if overweight or obese 3, 4, 5
• Avoid alcohol, especially beer and spirits 3, 4, 5
• Eliminate sugar-sweetened drinks and foods high in fructose 3, 4, 5
• Reduce intake of red meat and seafood 3, 4, 5
• Encourage low-fat dairy products, particularly skim milk 3, 5
• Regular exercise to reduce mortality associated with hyperuricemia 3

Comorbidity Management

• If taking thiazide or loop diuretics, substitute if possible 3
• Switch to losartan (which has modest uricosuric effects) or calcium channel blockers for hypertension management 3
• Consider fenofibrate for hyperlipidemia, which has uricosuric properties 3
• Optimize diabetes control, as hyperglycemia worsens hyperuricemia 3
• Review all medications for urate-raising effects 3